FCGR2A and COVID-19: As the resulting ACE2-Mb TM lacks those amino acids needed for interaction with the FcγR and C1q of the complement cascade (67), we expect that the ACE2-Mb TM should not harbor the risk of COVID-19 exacerbation via ADE.